Crossmark

Generation of macrophage containing alveolar organoids derived from human pluripotent stem cells for pulmonary fibrosis modeling and drug efficacy testing

Crossref DOI link: https://doi.org/10.1186/s13578-021-00721-2

Published Online: 2021-12-18

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heo, Hye-Ryeon

Hong, Seok-Ho http://orcid.org/0000-0003-3372-442X
Funding

Funding for this research was provided by:

Bio & Medical Technology Development Program of the National Research Foundation (2017M3A9B3061838, 2019R1A2C2005453)
License Information

Text and Data Mining valid from 2021-12-01

Version of Record valid from 2021-12-18
More Information

Article History

Received: 25 September 2021

Accepted: 18 November 2021

First Online: 18 December 2021

Declarations

:

: This study was approved and supervised by Ethical committee of Kangwon National University Hospital and Hallym University Medical Center. Written informed consent was provided by all participants.

: Not applicable.

: The NP-011 and the use of NP-011 for treating liver and lung fibrosis is protected by published and unpublished patents (KOR/10-1947902, PCT/ KR2017/005150, EU/17870624.8, JP/2018-524465, US/15/994.323, CN/ 201780004259.5, KOR/10-2018-0128625, and PCT/KR2018/012801), and these intellectual property rights are belonging to NEXEL. Co., Ltd.

Document is current

Any future updates will be listed below